Market
Region receiving largest share of Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Distribution reports from Global Fund and PEPFAR, regional health organization updates
Story
Global Fund and PEPFAR to Distribute Lenacapavir, 100% Success Rate, to 2 Million People by 2026
Dec 17, 2024, 03:09 PM
A new long-acting preventive drug for HIV, known as Lenacapavir, is set to be distributed in the world's poorest countries by late 2025 or early 2026. This initiative is part of a coordinated effort by the Global Fund and PEPFAR, aiming to reach 2 million people with the drug, which has shown 100% success in trials. Health officials believe that this drug could significantly reduce global HIV infections and accelerate the fight against the virus by 2030.
View original story
Similar markets
Asia • 25%
North America • 25%
Europe • 25%
Africa • 25%
Southeast Asia • 25%
Other • 25%
Sub-Saharan Africa • 25%
South America • 25%
South Asia • 25%
Latin America • 25%
Southeast Asia • 25%
Sub-Saharan Africa • 25%
North America • 25%
Asia • 25%
Africa • 25%
Europe • 25%
Africa • 25%
European Union • 25%
United States • 25%
Other • 25%
Asia • 25%
Africa • 25%
Europe • 25%
North America • 25%
10-14 countries • 25%
15 or more countries • 25%
1-4 countries • 25%
5-9 countries • 25%
Clinics • 25%
Pharmacies • 25%
Hospitals • 25%
Community health programs • 25%
South Africa • 25%
United States • 25%
Other • 25%
European Union • 25%
Elderly • 25%
Adolescents • 25%
Adults • 25%
Pregnant women • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%